Publications by authors named "H Bohnenberger"
[New methods at the transition from research to routine diagnostics].
Pathologie (Heidelb)
January 2025
Background: Pathology, traditionally focused on classification and diagnosis, is continuously evolving through new technologies. Advances in proteomics, epigenetics, tissue staining, and 3D imaging expand the possibilities of classical morphology.
Aim Of The Study: The aim of this study was to investigate how modern technologies can improve diagnostic accuracy and therapy selection and how they can be integrated into pathologic routine diagnostics.
Article Synopsis
- Esophageal cancer has a poor prognosis, and while neoadjuvant chemoradiotherapy (CRT) followed by immunotherapy shows promise, the effect of CRT on PD-L1 expression in these cancers is not fully understood.
- The study investigated PD-L1 expression changes in esophageal adenocarcinoma and squamous cell carcinoma cell lines after treatment with chemotherapy and CRT, finding that Carboplatin and CRT led to the highest increases in PD-L1 expression.
- Despite observed increases in PD-L1 with certain treatments, the overall conclusion was that neoadjuvant CRT according to the CROSS protocol did not significantly alter PD-L1 expression when comparing pre- and post-treatment levels in patient samples.
Expression and prongostic impact of galectin-7 in human lung cancer.
Medicine (Baltimore)
October 2024
Malignant tumors of the lung are the leading cancers worldwide. Prognostic biomarkers continue to be investigated for the detection and stratification of lung cancer for clinical use. In breast cancer cells and in lymphomas, the overexpression of galectin-7 led to increased metastasis.
View Article and Find Full Text PDFArticle Synopsis
- Preclinical studies suggest that combining MEK inhibition with autophagy or CDK4/6 targeting may be beneficial for pancreatic cancer (PDAC) patients.
- A retrospective analysis of 34 patients treated with trametinib combined with hydroxychloroquine (THCQ) or palbociclib (TP) was conducted to evaluate the effectiveness of these regimens.
- Results showed that both combinations were ineffective, with most patients experiencing disease progression within a short time frame, highlighting the need for better treatment strategies for advanced PDAC with specific genetic mutations.
Background And Aim: The German NPC-GPOH trials introduced treatment including neoadjuvant chemotherapy, radiochemotherapy (RCT) and antiviral treatment in patients aged 25 years or younger with nasopharyngeal cancer (NPC). We conducted a retrospective study on outcomes of patients at the age of ≥26 years treated accordingly at our institution.
Methods: Consecutive patients who received primary RCT for NPC were included.